Skip to content

Study · Systematic review · 2025

1 result

GLP-1 receptor agonists and alcohol use disorder: a systematic review.

Patel S, Blaney H, Nassar S, Singal AK, Singal AK

Alcohol and alcoholism (Oxford, Oxfordshire)1 Nov 2025

PMID41273789 (opens in a new tab)DOI10.1093/alcalc/agaf069 (opens in a new tab)PepBankPUB-41273789
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a systematic review of randomized trials in alcohol use disorder, semaglutide reduced alcohol use.

    In plain wordsIn a review of three trials on alcohol use, semaglutide reduced alcohol use.

    Peptide
    Semaglutide
    Outcome
    DecreaseAlcohol use
    Study

    n: not reported in source

    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    semaglutide reduced alcohol use
    1 context sentence
    Summary · context
    In this review of three randomized controlled trials (RCTs) (n = 48-151)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.